Kura Oncology, Inc. (KURA)

Kura Oncology, Inc. (KURA) Healthcare & Pipeline Overview

Kura Oncology, Inc. is a clinical-stage biotechnology firm specializing in small molecule cancer therapies, advancing lead candidates ziftomenib for acute leukemias and tipifarnib for solid tumors. The company leverages targeted approaches and strategic collaborations, including one with Novartis, to address genetically defined subsets of various cancers.

What Is the Investment Thesis for KURA?

Kura Oncology, Inc. presents a research focus on developing targeted small molecule therapies for cancer, with its value drivers primarily linked to the progression and potential commercialization of its clinical-stage pipeline. The company's lead candidates, ziftomenib and tipifarnib, address genetically defined subsets of acute leukemias and various solid tumors, respectively, representing significant unmet medical needs. The ongoing Phase II trials for tipifarnib and the clinical collaboration with Novartis for head and neck squamous cell carcinoma underscore potential for future data readouts and strategic partnerships. Financially, Kura Oncology operates as a clinical-stage entity, reflected in its negative P/E ratio of -3.27 and a profit margin of -411.2%, indicative of substantial R&D investment typical for biopharmaceutical development. Its free cash flow stands at $-0.13B, necessitating ongoing capital management. However, a gross margin of 94.7% suggests strong potential profitability if product candidates reach market. Future growth is contingent on successful clinical trial outcomes, regulatory approvals, and potential commercialization or licensing agreements, which could significantly impact its current market capitalization of $979.18M. The company's beta of 0.32 suggests lower volatility relative to the broader market, though clinical-stage biotechs inherently carry high idiosyncratic risk.

Based on FMP financials and quantitative analysis

KURA Key Highlights

• Market Capitalization: Kura Oncology maintains a market capitalization of $979.18M, reflecting its valuation as a clinical-stage biopharmaceutical company with a pipeline of oncology assets.
• Profitability Metrics: The company reported a significant negative profit margin of -411.2% and a negative P/E ratio of -3.27, which is characteristic of a biopharmaceutical firm heavily investing in research and development prior to product commercialization.
• Gross Margin Performance: Kura Oncology achieved a gross margin of 94.7%, indicating strong potential for profitability on future product sales, assuming successful development and market entry of its drug candidates.
• Free Cash Flow: The company's free cash flow stands at $-0.13 billion, demonstrating the substantial capital required to fund ongoing clinical trials and research activities in its current development stage.
• Market Volatility: With a Beta of 0.32, Kura Oncology exhibits lower sensitivity to overall market movements compared to the average stock, although its specific clinical development risks are significant.

Who Are KURA's Competitors?

KURA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KURA's Key Strengths?

• Focused pipeline of small molecule inhibitors for specific cancer targets.
• Lead candidates ziftomenib and tipifarnib address high unmet medical needs.
• Strategic clinical collaboration with Novartis for tipifarnib.
• Strong gross margin potential (94.7%) if products reach market.

What Are KURA's Weaknesses?

• Clinical-stage company with no commercialized products, leading to negative profitability (-411.2% profit margin, $-0.13B FCF).
• High capital requirements for ongoing R&D and clinical trials.
• Reliance on successful progression of a limited number of lead candidates.
• Negative P/E ratio of -3.27 reflects current unprofitability.

What Could Drive KURA Stock Higher?

• Ziftomenib Clinical Trial Data Readouts: Anticipated release of further clinical data from ongoing trials for ziftomenib in acute myeloid leukemia and acute lymphoblastic leukemia. Positive results could significantly de-risk the asset and pave the way for pivotal studies.
• Tipifarnib Phase II Trial Progression: Continued advancement and enrollment in Phase II clinical trials for tipifarnib across various solid tumors and hematologic indications, including the specific head and neck squamous cell carcinoma cohort.
• Novartis Collaboration Milestones: Achievement of specific clinical or regulatory milestones within the collaboration with Novartis for tipifarnib and alpelisib in head and neck squamous cell carcinoma, potentially triggering payments or expanded development.
• Pipeline Expansion Announcements: Introduction of new preclinical or early-stage clinical candidates into the pipeline, signaling continued innovation and long-term growth prospects beyond current lead assets.

What Are the Key Risks for KURA?

• Financial-distress signal — its Altman Z-Score of -2.00 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical Trial Failures: The primary risk for Kura Oncology is the potential for lead product candidates, ziftomenib and tipifarnib, to fail in ongoing or future clinical trials due to lack of efficacy or unacceptable safety profiles. Such failures could lead to significant pipeline setbacks and impact company valuation.
• Regulatory Approval Uncertainty: As a clinical-stage company, Kura Oncology faces inherent uncertainty in obtaining regulatory approvals from bodies like the FDA. The approval process is rigorous, lengthy, and subject to evolving guidelines, potentially causing delays or outright rejection of drug candidates.
• Funding and Capital Requirements: Developing novel cancer therapies is highly capital-intensive. Kura Oncology's negative free cash flow of $-0.13B indicates ongoing reliance on external financing, which could lead to future equity dilution or challenges in securing sufficient capital to complete clinical programs.
• Intense Competition: The oncology market is highly competitive, with numerous pharmaceutical and biotechnology companies developing similar or alternative treatments. Kura Oncology's candidates face competition from established therapies and other investigational drugs, which could impact market share and pricing power upon commercialization.

What Are the Growth Opportunities for KURA?

• Advancement of Ziftomenib in Acute Leukemias: Kura Oncology's lead candidate, ziftomenib, targets the menin-KMT2A protein-protein interaction for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). These leukemias represent significant unmet needs, particularly in relapsed/refractory settings. The global acute leukemia market is projected to reach substantial valuations, with AML alone estimated to be a multi-billion dollar market. Successful progression through clinical trials, positive data readouts, and eventual regulatory approval for ziftomenib could unlock a significant revenue stream, establishing Kura Oncology as a key player in targeted leukemia therapies within the next 3-5 years.
• Expansion of Tipifarnib Indications: Tipifarnib, an orally bioavailable farnesyl transferase inhibitor, is currently in Phase II trials for solid tumors and hematologic indications. Its potential application across multiple cancer types, including head and neck squamous cell carcinoma (HNSCC) through the Novartis collaboration, offers diversified growth avenues. The HNSCC market, for instance, is a considerable segment within oncology. Expanding tipifarnib's utility beyond its initial focus could significantly broaden its market reach and commercial potential, with further clinical data expected to emerge over the next 2-4 years.
• Strategic Collaboration with Novartis: The clinical collaboration with Novartis to evaluate tipifarnib and alpelisib in HNSCC patients with specific genetic markers (HRAS overexpression or PIK3CA mutation/amplification) represents a crucial growth opportunity. Such partnerships provide not only validation of Kura's assets but also access to additional resources, expertise, and potential future commercialization pathways. A successful outcome from this collaboration could lead to expanded development, co-commercialization agreements, or milestone payments, significantly de-risking development and accelerating market entry for tipifarnib in this specific indication within a 3-6 year timeframe.
• Pipeline Expansion and Discovery: As a clinical-stage biopharmaceutical company, Kura Oncology's long-term growth is inherently tied to the continuous innovation and expansion of its pipeline beyond its current lead candidates. Investing in new drug discovery programs and identifying novel targets for oncology could lead to future product candidates addressing other high-value cancer markets. This ongoing research and development effort, while capital-intensive, is critical for sustainable growth and maintaining a competitive edge in the rapidly evolving oncology landscape, with new preclinical candidates potentially entering trials within 5-7 years.
• Potential for Regulatory Approvals and Commercialization: The ultimate growth driver for Kura Oncology lies in achieving regulatory approvals for its lead product candidates, ziftomenib and tipifarnib. Successful navigation of Phase III trials (for ziftomenib) and subsequent FDA approval would transition the company from a clinical-stage to a commercial-stage entity. This transition would unlock direct revenue generation from product sales, transforming its financial profile from R&D-heavy to a revenue-generating model. The market for novel cancer therapeutics is substantial, and even a small market share could generate significant returns, with initial commercialization potentially commencing within 4-7 years post-approval.

What Opportunities Does KURA Have?

• Successful clinical trial outcomes for ziftomenib and tipifarnib leading to regulatory approvals.
• Expansion of tipifarnib's indications beyond current Phase II trials.
• Potential for new collaborations or licensing agreements for pipeline assets.
• Growth in the precision oncology market for genetically defined cancers.

What Threats Does KURA Face?

• Clinical trial failures or unexpected adverse events.
• Intense competition from larger pharmaceutical companies and other biotechs.
• Regulatory hurdles and delays in the drug approval process.
• Need for significant future funding, potentially leading to share dilution.

What Are KURA's Competitive Advantages?

• Targeted Small Molecule Pipeline: Proprietary small molecule inhibitors like ziftomenib (menin-KMT2A) and tipifarnib (farnesyl transferase) target specific, validated cancer pathways, offering a differentiated approach.
• Intellectual Property: Patents protecting its lead drug candidates and their mechanisms of action provide a period of market exclusivity.
• Clinical Development Expertise: Specialized knowledge in navigating complex oncology clinical trials, particularly for genetically defined patient populations.
• Strategic Collaborations: Partnerships, such as the one with Novartis, validate its assets and provide access to additional resources, expertise, and potential market reach.

What Does KURA Do?

Kura Oncology, Inc., established in 2014 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule medicines for cancer treatment within the United States. The company's strategic focus is on addressing significant unmet medical needs in oncology through a pipeline of targeted therapies. Its foundational approach involves identifying and developing product candidates that modulate specific molecular pathways implicated in cancer progression. Kura Oncology's evolution has centered on advancing its lead programs through various clinical trial stages, aiming to bring novel treatments to patients with genetically defined subsets of cancers. The company's primary product candidates include ziftomenib, a small molecule inhibitor designed to target the menin-Lysine K-specific Methyltransferase 2A (menin-KMT2A) protein-protein interaction. Ziftomenib is being developed for the treatment of acute leukemias, specifically acute myeloid leukemia and acute lymphoblastic leukemia, which are often characterized by specific genetic alterations. This candidate represents a precision medicine approach to a challenging group of hematologic malignancies. Another key asset in Kura Oncology's pipeline is tipifarnib, an orally bioavailable inhibitor of farnesyl transferase. Tipifarnib is currently undergoing Phase II clinical trials, exploring its potential in both solid tumors and various hematologic indications. The company has also forged a significant clinical collaboration with Novartis, a major pharmaceutical entity. This collaboration is focused on evaluating the combination of tipifarnib with alpelisib in patients diagnosed with head and neck squamous cell carcinoma (HNSCC). This specific patient population is characterized by tumors exhibiting HRAS overexpression or PIK3CA mutation and/or amplification, highlighting Kura Oncology's commitment to biomarker-driven therapeutic development. Through these initiatives, Kura Oncology aims to establish a strong market position in targeted oncology therapeutics.

What Products and Services Does KURA Offer?

• Develops small molecule product candidates for cancer treatment.
• Focuses on genetically defined subsets of acute leukemias with ziftomenib.
• Advances tipifarnib for solid tumors and hematologic indications.
• Conducts Phase II clinical trials for tipifarnib.
• Engages in clinical collaborations, such as with Novartis, for combination therapies.
• Researches and develops targeted therapies to address specific molecular pathways in cancer.
• Headquartered in San Diego, California, operating in the United States.

How Does KURA Make Money?

• Primarily focused on research and development (R&D) of novel cancer therapeutics.
• Generates value through the progression of drug candidates through clinical trials.
• Seeks potential future revenue from product sales upon regulatory approval.
• Engages in strategic collaborations and partnerships, potentially involving milestone payments or royalties.
• Relies on capital raises (equity financing, debt) to fund extensive R&D activities and clinical trials.

What Industry Does KURA Operate In?

Kura Oncology, Inc. operates within the highly specialized and capital-intensive Biotechnology industry, specifically focusing on oncology. This sector is characterized by extensive research and development cycles, stringent regulatory pathways, and a high degree of innovation aimed at addressing complex diseases like cancer. The broader healthcare sector, particularly oncology, continues to experience robust growth driven by an aging global population, increasing cancer incidence, and advancements in personalized medicine. Kura Oncology's strategy of developing small molecule inhibitors for genetically defined cancer subsets aligns with the industry trend towards precision oncology, which seeks to tailor treatments based on a patient's genetic profile. The competitive landscape is intense, featuring both large pharmaceutical companies with vast resources and numerous smaller, clinical-stage biotechs vying for breakthroughs. Kura Oncology differentiates itself through its specific drug targets, such as the menin-KMT2A interaction for acute leukemias and farnesyl transferase inhibition for solid tumors, aiming to carve out niche markets with high unmet medical needs.

Who Are KURA's Key Customers?

• Oncology patients suffering from acute leukemias, solid tumors, and other hematologic indications.
• Healthcare providers and oncologists who prescribe cancer treatments.
• Pharmaceutical partners for potential licensing, co-development, or co-commercialization agreements.
• Hospitals and clinics that administer cancer therapies.

Key Financial Metrics

Return on assets is -45.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -30.8%, the inverse of the P/E and a quick read on earnings relative to price.

Kura Oncology, Inc. (KURA) Valuation Context

Valued at $979.18M, KURA is classified as a small-cap stock. Relative to its peer group, KURA's quantitative score of 10/100 is below the peer average of 76/100.

Company Profile

Kura Oncology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Troy Edward Wilson. KURA has traded publicly since 2015.

F-Score 2/9Financial Health

Kura Oncology, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.00 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Kura Oncology, Inc. revenue of about $95.0M for fiscal 2026, with EPS near $-3.54. The estimate reflects 11 contributing analysts.

Net buyingInsider Activity

Over the past six months, Kura Oncology, Inc. insiders filed 30 SEC Form 4 transactions — 19 sales and 11 purchases. On net that is roughly 148K shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.

KURA Financials

KURA Latest News

KURA Analyst Consensus

KURA MoonshotScore

Latest Kura Oncology, Inc. Analysis

What Investors Ask About Kura Oncology, Inc. (KURA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources